Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2,395 GBp
Change Today -10.00 / -0.42%
Volume 554.9K
HIK On Other Exchanges
Symbol
Exchange
London
OTC US
OTC US
Frankfurt
As of 11:35 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

hikma pharmaceuticals plc (HIK) Snapshot

Open
2,420 GBp
Previous Close
2,405 GBp
Day High
2,420 GBp
Day Low
2,374 GBp
52 Week High
02/25/15 - 2,612 GBp
52 Week Low
09/26/14 - 1,577 GBp
Market Cap
4.8B
Average Volume 10 Days
514.6K
EPS TTM
1.40 GBp
Shares Outstanding
199.3M
EX-Date
04/16/15
P/E TM
26.7x
Dividend
0.25 GBp
Dividend Yield
0.96%
Current Stock Chart for HIKMA PHARMACEUTICALS PLC (HIK)

Related News

No related news articles were found.

hikma pharmaceuticals plc (HIK) Related Businessweek News

View More BusinessWeek News

hikma pharmaceuticals plc (HIK) Details

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms in the Middle East and North Africa, the United States, Europe, the United Kingdom, and internationally. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 499 products in 1,256 dosage strengths and forms in the anti-infective, cardiovascular, central nervous system (CNS), and diabetes therapeutic areas. The Injectables segment markets 200 branded and non-branded products in 379 dosage strengths and forms for CNS, anti-infective, cardiovascular, and oncological therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. The Generics segment provides 11 products in 44 dosage strengths and forms for various therapeutic areas including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory, hormonal, and others. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. The company also offers anesthetics, anti-histamines, gastroenterology and metabolism, musculoskeletal system, dermatology, genitourinary system, transplantation, vitamins and supplements, and miscellaneous products. In addition, it manufactures plastic specialized medicinal sterile containers; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, United Kingdom.

7,139 Employees
Last Reported Date: 03/11/15
Founded in 1978

hikma pharmaceuticals plc (HIK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $2.1M
Executive Vice Chairman, Member of Compliance...
Total Annual Compensation: $1.6M
Compensation as of Fiscal Year 2014.

hikma pharmaceuticals plc (HIK) Key Developments

Hikma Mulls Acquisitions

Hikma Pharmaceuticals PLC (LSE:HIK) is seeking acquisitions. Khalid Nabilsi, Chief Financial Officer of Hikma, said, "We still have a strong balance sheet, which will allow us to do further small bolt-on acquisitions. So our leverage are going -- we can't give guidance on the leverage at this stage, due to the circular, but it's going to be in line with what we've guided somewhat in the past."

Boehringer Ingelheim Roxane Inc., Hikma Pharmaceuticals PLC, Roxane Laboratories, Inc. - M&A Call

To discuss acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim

Hikma Pharmaceuticals PLC Appoints Kofi Amegashie as Head of Sub-Saharan African Business

Hikma Pharmaceuticals PLC has appointed Kofi Amegashie as head of its newly created sub-Saharan African business. Kofi will lead Hikma's expansion into this region with the aim of replicating Hikma's brand success in the Middle East and North Africa and establishing a strong foot hold in East, West and Francophone Africa. He was most recently Managing Director - Africa, at Adcock Ingram Healthcare Pty. Ltd., with responsibility for all business operations in Africa, outside of South Africa.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HIK:LN 2,395.00 GBp -10.00

HIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $46.11 USD -0.22
Impax Laboratories Inc $48.46 USD +0.10
Pfizer Ltd/India 2,176 INR 0.00
Sagent Pharmaceuticals Inc $24.58 USD -0.30
Medicines Co/The $31.39 USD +0.99
View Industry Companies
 

Industry Analysis

HIK

Industry Average

Valuation HIK Industry Range
Price/Earnings 26.9x
Price/Sales 5.0x
Price/Book 6.2x
Price/Cash Flow 26.8x
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HIKMA PHARMACEUTICALS PLC, please visit www.hikma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.